medwireNews: Giving semaglutide to folks present process minimally invasive endoscopic sleeve gastroplasty (ESG) could carry weight reduction nearer to that induced by bariatric surgical procedure, reveals analysis.
The small randomized examine, because of be offered on the digital Digestive Disease Week 2021, concerned 58 individuals present process ESG, who had been assigned to take semaglutide at a most dose of 1.5 mg/week or placebo, ranging from inside 1 month of the process.
Both teams misplaced weight, however from round 6 months, weight reduction within the semaglutide group started to outstrip that of the placebo group, reaching a median of 26.7% by the tip of the 11-month follow-up, in contrast with 19.6% amongst these given placebo.
Participants within the semaglutide group additionally misplaced a median 12.69% of their fats mass, whereas the placebo group misplaced a considerably smaller 9.04%, and their common glycated hemoglobin stage was considerably decrease.
Presenting the info to press, Anna Carolina Hoff (Angioskope Brazil, São José dos Campos) famous that the burden loss outcomes achieved with ESG plus semaglutide “method bariatric surgical procedure outcomes.”
But she added that surgical procedure is indicated solely at a excessive BMI, or after comorbidities have developed, and solely 2% of eligible folks bear the process. By distinction, she mentioned, ESG could be carried out at a decrease BMI, making it obtainable to extra folks, together with those that don’t want to bear surgical procedure.
medwireNews is an impartial medical information service offered by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, a part of the Springer Nature Group
